New hope for stubborn muscle weakness? drug targets immune cells in tiny trial
NCT ID NCT07499323
First seen Apr 20, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This very early study will test a drug called talquetamab in just 2 people with refractory generalized myasthenia gravis, a chronic autoimmune disease that causes severe muscle weakness and has not improved with standard treatments. Talquetamab works by directing the body's immune T cells to destroy certain cells that may be driving the disease. The goal is to see if the drug can safely reduce symptoms and improve daily functioning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.